Zentalis Pharmaceuticals Inc（ZNTL）財務資料ZNTLZentalis Pharmaceuticals Inc

Evaluating the bottom line, Zentalis Pharmaceuticals, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -66.75%, provide a clear picture of how effectively ZNTL converts its operational activities into shareholder value.

In the context of the broader market, ZNTL competes directly with industry leaders such as WHWK and UPB. With a market capitalization of $161.89M, it holds a significant position in the sector. When comparing efficiency, ZNTL's gross margin of N/A stands against WHWK's N/A and UPB's 100.00%. Such benchmarking helps identify whether Zentalis Pharmaceuticals, Inc. is trading at a premium or discount relative to its financial performance.

Zentalis has shown significant financial challenges, with a net income of -$42,286,000 in Q2 2026 and a gross margin of 0% in recent quarters, indicating ongoing operational difficulties.